Hutchmed Completes Enrollment in Phase II Trial of Fanregratinib in FGFR2-Altered Cholangiocarcinoma
The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback